

## **How Cancer Cells Escape Death**

**Coordinated by the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the University of Ulm, scientists are collaborating in a new Helmholtz Virtual Institute to study how leukemia cells become resistant to programmed cell death and to chemotherapy. Their aim is to find out how this resistance can be overcome in order to facilitate better cancer treatment.**

Programmed cell death, or apoptosis, is a protective mechanism of the body to prevent cells with damaged genetic material from becoming dangerous for the whole organism. In cancer cells, however, this protective mechanism often fails and they become resistant to those signals that order them to commit suicide. This is particularly fatal, because the effective mechanism of many types of chemotherapy is to trigger apoptosis.

Cancer researchers are therefore trying to find out how resistance to apoptosis evolves in cancer and how it may be overcome. "For successful treatment of cancer it is crucial to understand resistance to apoptosis and chemotherapy," says Professor Dr. Peter Lichter of DKFZ, who is one of two coordinators of the Virtual Institute.

The collaborating scientists have chosen chronic lymphocytic leukemia (CLL), the most common leukemia in adults, as a model system. "Our collaboration partners have a great deal of experience with this cancer. And we also expect that mechanisms identified in CLL will apply to other types of cancer, too," says Dr. Daniel Mertens of Ulm University, the other coordinator of the research collaboration.

Researchers collaborating in the new Virtual Institute are investigating, on the one hand, the signals which cancer cells exchange with their surrounding tissues. On the other hand, the investigators are searching the whole genome of leukemia cells to identify sequence alterations of genes and chemical modifications of individual genetic building blocks which change gene activity. By these approaches they hope to identify new target molecules that are characteristic of resistance to apoptosis and can be used as targets for enhanced anticancer drugs. In a parallel effort, the collaborators will search through large substance libraries to find substances which are able to specifically block newly discovered target molecules.

Alongside DKFZ scientists, members of the Virtual Institute are scientists of the National Center for Tumor Diseases (NCT) Heidelberg, of the Universities of Duisburg, Essen, Ulm and Würzburg as well as from the U.K. and Denmark.

"Virtual Institutes" are a funding model of the Helmholtz Association of National Research Centers in Germany to support research networks with universities and other partners within the science system. The aim is to offer an unbureaucratic framework for researchers to push forward high-potential research projects in a collaborative effort. The Virtual Institute will be launched on August 1, 2011, and will receive funds of 3.65 million euros over a five-year period.

For more information please visit:

[www.leukemia-resistance.de](http://www.leukemia-resistance.de)

A picture is available at the Internet.

[http://www.dkfz.de/de/presse/pressemitteilungen/2011/images/lichter\\_mertens\\_17p\\_fish.jpg](http://www.dkfz.de/de/presse/pressemitteilungen/2011/images/lichter_mertens_17p_fish.jpg)

Legend: A single red signal in the nucleus of leukemia cells indicates a partial loss of chromosome 17 leading to resistance to apoptosis and chemotherapy

Picture Source: Daniel Mertens, German Cancer Research Center and University Ulm

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), employing over 2,500 staff members, is the largest biomedical research institute in Germany. More than 1,000 scientists are working to investigate the mechanisms of cancer development, identify cancer risk factors and develop new strategies for better cancer prevention, more precise diagnosis and effective treatment of cancer patients. In addition, the staff of the Cancer Information Service (KID) provides information about this widespread disease for patients, their families, and the general public. DKFZ is funded by the German Federal Ministry of Education and Research (90%) and the State of Baden-Wuerttemberg (10%) and is a member of the Helmholtz Association of National Research Centers.

Dr. Stefanie Seltmann  
Head of Press and Public Relations  
German Cancer Research Center  
Im Neuenheimer Feld 280  
D-69120 Heidelberg  
T: +49 6221 42 2854  
F: +49 6221 42 2968  
[presse@dkfz.de](mailto:presse@dkfz.de)